Home New Customer? Create Account
Member Login:

Kanamycin Selection Plasmids



Starting at: $307.00

Please Choose:

Shipping Option

Enter Quantity:

This plasmid is compatible with all of the other DNA sequences available on this site, which are all sold in the same backbone. This flexibility allows you to create any vector you require, with a variety of functions, simply by compiling the relevant sections from our product range.


Product Code: OG314

Quantity Provided: 5µg

Size (bp): 4259

Bacterial Antibiotic Selection: Kanamycin

Origin and Compatibility: pUC high copy, derived from pBR322   

Copy Number: 500-700 copies per cell

Promoter: Cytomegalovirus (CMV) immediate early promoter

Purpose: This vector adds an influenza HA epitope tag that allows protein detection or purification using antibodies against raised against the HA tag. The HA tag will be positioned at the 3’ end (C-terminus) of a gene (expressed protein) in the primary MCS (NotI-XbaI, but XbaI is ablated in this vector to allow read through into the tag coding sequence). The HA tag coding sequence is YPYDVPDYA. This sequence is downstream of an enterokinase cleavage site (DDDDK) that can be used to remove the tag from a purified protein if required. It cleaves after the lysine residue.   

Quality Validation: This vector has been demonstrated to express reporter genes to high levels under the CMV promoter with HA tag fused to the C-terminus of the reporter gene coding sequence. The start codon of these reporters was positioned within the NcoI site and the stop codon was positioned downstream of the HA tag coding sequence. The presence of the peptide reduced the activity of the reporter gene by 2.9-fold, however, all of our other C-terminal tags (except GST) reduced expression by an equal amount, suggesting the effect was independent of the HA tag sequence itself, and only an inherent property of the reporter used. Expression was validated in the A549 lung carcinoma cell line. 

Quality Sequencing Analysis: This vector has been fully sequenced using primers F1-F10. The sequences and details of these primers are available through our website.

Intellectual Property Status: According to our IP-friendly policy, this plasmid is sold free of reach-through rights on any derivatives you may create.

Genetic Modifications to standard parts:

  • CMV promoter – an NcoI site has been ablated in the CMV promoter. This change does not reduce expression.
  • KanR cassette – This KanR resistance region is not a wild type sequence, it has been modified to remove all restriction sites that conflict with the SnapFastTM system and to retain a high level of antibiotic resistance. It has been validated in E.coli.

Restriction site notes:

  • Bgl2, KpnI, SwaI and PmeI each cut the vector at two sites positioned to flank the promoter, start codon, origin, and KanR, respectively.